Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Heart Failure
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Patients with Obesity
100%
Semaglutide
100%
Placebo
83%
Heart Failure with Preserved Ejection Fraction (HFpEF)
83%
95% Confidence Interval
83%
Obesity
33%
C-reactive Protein
33%
Composite Endpoint
33%
Changes in Body Weight
33%
Physical Limitations
33%
6-minute Walk Distance (6MWD)
33%
Hierarchical Composites
33%
Body Mass Index
16%
Placebo Groups
16%
High-score
16%
Patients with Heart Failure
16%
Weight Loss
16%
Serious Adverse Events
16%
Large Reduction
16%
Symptom Burden
16%
Heart Failure Events
16%
Kansas City Cardiomyopathy Questionnaire
16%
Walking Distance
16%
Novo Nordisk
16%
Clinical Summary
16%
Win Ratio
16%
Once-weekly Semaglutide
16%
Semaglutide 2.4 Mg
16%
Between-groups Differences
16%
Change from Baseline
16%
Nursing and Health Professions
Congestive Heart Failure
100%
Patient with Obesity
100%
Semaglutide
100%
Placebo
85%
Confidence Interval
71%
Heart Failure with Preserved Ejection Fraction
57%
Walking Distance
42%
Body Weight
28%
C Reactive Protein
28%
Body Mass
14%
Adverse Event
14%
Randomization
14%
Myocardial Disease
14%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Congestive Heart Failure
100%
Patient with Obesity
100%
Semaglutide
100%
Placebo
85%
Heart Failure with Preserved Ejection Fraction
57%
Body Weight
28%
C Reactive Protein
28%
Body Mass Index
14%
Adverse Event
14%
Myocardial Disease
14%